Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2GL47)

Drug Name
Isoflavone derivative 5 Drug Info
Synonyms PMID26666870-Compound-23
Cross-matching ID
TTD Drug ID
DM2GL47

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Zinc finger protein GLI1 (Gli1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Isoflavone derivative 1 DMMCWH9 N. A. N. A. Patented [1]
Isoflavone derivative 7 DMNCHBL N. A. N. A. Patented [1]
Isoflavone derivative 8 DMN0XJQ N. A. N. A. Patented [1]
Isoflavone derivative 9 DMA78MD N. A. N. A. Patented [1]
Isoflavone derivative 6 DM2ZYVL N. A. N. A. Patented [1]
Isoflavone derivative 3 DMYFKR2 N. A. N. A. Patented [1]
Isoflavone derivative 2 DMTWAH3 N. A. N. A. Patented [1]
Isoflavone derivative 4 DMYRU7I N. A. N. A. Patented [1]
PMID26666870-Compound-16 DMMGQ7Z N. A. N. A. Patented [1]
Imidazo bicyclic iminium derivative 1 DM01RXU N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Smoothened homolog (SMO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [2]
Vismodegib DM5IXKQ Basal cell carcinoma 2C32 Approved [3]
LDE225 DMM9F25 Basal cell carcinoma 2C32 Phase 2 [4]
LY2940680 DMTJWIQ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
BMS-833923 DM459Q7 Solid tumour/cancer 2A00-2F9Z Phase 1b [5]
LEQ-506 DM5INZP Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
TAK-441 DM7DFBL Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PMID25726713-Compound-49 DM2CT4G N. A. N. A. Patented [8]
PMID25726713-Compound-51 DMF0OW4 N. A. N. A. Patented [8]
PMID25726713-Compound-48 DMSIOUA N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Smoothened homolog (SMO) TT8J1S3 SMO_HUMAN Inhibitor [1]
Zinc finger protein GLI1 (Gli1) TTJOMH6 GLI1_HUMAN Inhibitor [1]

References

1 Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
5 Clinical pipeline report, company report or official report of Exelixis (2011).
6 Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
7 TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66.
8 Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.